UNSPSC 51263140: Celiprolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C20H33N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DRB57K47QC, chemically known as urea, n-(3-acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-n,n-diethyl- but generally known as celiprolol, which bears US NIH Compound Identifier 2663. European Medicines Agency schedules Celiprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07436MIG.

UNSPSC 51263140 Celiprolol is a Commodity code that in practice encompasses pharmaceutical procurement by state and local health agencies, though recent solicitation activity shows significant mismatch with the code's nominal scope. The Seminole County, Florida opportunity tags naloxone and drug deactivation systems under this celiprolol code, and the Texas Health and Human Services Commission RFI addresses direct-to-manufacturer prescription fulfillment programs — neither directly related to celiprolol, a beta-blocker cardiovascular medication. State and local health departments and human services agencies appear to use this code to classify broader pharmaceutical and medical-product procurement, not celiprolol specifically. The issuing bodies include county health systems and state HHS commissions managing pharmacy benefit programs and community health initiatives.

Recent activity centers in Florida and Texas. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs serving self-insured employer and state agency health plans. The code shows sparse recent activity overall, and the opportunities posted under it do not align with celiprolol procurement — suggesting either inconsistent code assignment in state procurement systems or that this commodity code is not the primary vehicle for cardiovascular pharmaceutical purchases in state and local markets.